Pages that link to "Q88920081"

The following pages link to Alnylam terminates revusiran program, stock plunges (Q88920081):

Displaying 19 items.

• Advances in the delivery of RNA therapeutics: from concept to clinical reality. (Q38706445) (← links)
• 5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo (Q41510865) (← links)
• Evaluation and control of miRNA-like off-target repression for RNA interference (Q42777701) (← links)
• Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs (Q48569299) (← links)
• With Alnylam's amyloidosis success, RNAi approval hopes soar (Q50093518) (← links)
• Advances in lipid-lowering therapy through gene-silencing technologies (Q50123830) (← links)
• Worth the RISC? (Q52711221) (← links)
• Public biotech in 2016-the numbers. (Q53774078) (← links)
• Small-molecule-based regulation of RNA-delivered circuits in mammalian cells (Q57452395) (← links)
• Current Development of siRNA Bioconjugates: From Research to the Clinic (Q64085262) (← links)
• Clinical cancer nanomedicine (Q65556503) (← links)
• Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery (Q90362515) (← links)
• Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors (Q90635887) (← links)
• Alnylam launches era of RNAi drugs (Q91315076) (← links)
• The current state and future directions of RNAi-based therapeutics (Q92209450) (← links)
• Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? (Q92486932) (← links)
• Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone (Q92644016) (← links)
• Advances in oligonucleotide drug delivery (Q98386176) (← links)
• Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data (Q104103088) (← links)